Other leading causes include ischaemic heart diseases and diabetes.

Air conditioners won't be enough to solve the world's deadly heat problem.

The focus on COVID-19 shouldn't come at the expense of monitoring other diseases

(marketscreener.com) Aims to resolve patient diagnostic odyssey, often spanning years and multiple misdiagnoses before accurate diagnosisCombines cutting-edge technology and streamlined CE-IVD bioinformatics pipeline with the CENTOGENE Biodatabank, consisting of approximately 700,000 patients representing over 120 highly diverse countriesSignificantly reduces time and...https//www.marketscreener.com/quote/stock/CENTOGENE-N-V-74010961/news/CENTOGENE-Launches-NEW-CentoGenome-World-s-Most-Comprehensive-Whole-Genome-Sequencing-Solution-for-43474713/?utm_medium=RSS&utm_content=20230412

(marketscreener.com) NEW YORK, Jan. 5, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that Chaim Lebovits, President and CEO, and Stacy Lindborg, Co-CEO, will jointly present a corporate and clinical overview at 1030 a.m. PT on Monday, Jan. 9 at...https//www.marketscreener.com/quote/stock/BRAINSTORM-CELL-THERAPEUT-18118014/news/BrainStorm-Cell-Therapeutics-to-Present-at-Biotech-Showcase-trade-2023-42665197/?utm_medium=RSS&utm_content=20230105

(marketscreener.com) BERWYN, Pa., April 3, 2023 /PRNewswire/ -- Annovis Bio, Inc.  , a clinical-stage drug platform company addressing neurodegenerative diseases, has announced fourth quarter and full year financial results for the period ended December 31, 2022, and reviewed recent accomplishments. ...https//www.marketscreener.com/quote/stock/ANNOVIS-BIO-INC-102588345/news/ANNOVIS-BIO-ANNOUNCES-FOURTH-QUARTER-AND-FULL-YEAR-2022-FINANCIAL-RESULTS-AND-PROVIDES-CORPORATE-UPD-43414190/?utm_medium=RSS&utm_content=20230403

The telehealth service understood the federal health minister to have promised funding would be renewed from July but has learnt the money will only arrive in January.

FORMER Georgian President Mikheil Saakashvili has been diagnosed with 36 different diseases by doctors, as reported on Tuesday, November 8. Doctors have diagnosed former Georgian President Mikheil Saakashvili with 36 different diseases, including tuberculosis and dementia, his lawyer said. According to Shalva Khachapuridze, tests by doctors have shown the former president, who was also the […]The post British medical expert visits former Georgian President Mikheil Saakashvili after 36 different diseases diagnosis appeared first on Euro Weekly News.

(marketscreener.com) New Biomarkers of Response and Resistance that Suggest Pepinemab Could Offer New Combination Treatment OptionsROCHESTER, N.Y., Nov. 10, 2022 -- Vaccinex, Inc. , a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative diseases through the inhibition of semaphorin 4D , and its...https//www.marketscreener.com/quote/stock/VACCINEX-INC-45256990/news/Vaccinex-and-its-Collaborators-Present-Two-Abstracts-Related-to-Pepinemab-Combination-Immunotherapy-42271402/?utm_medium=RSS&utm_content=20221110

(marketscreener.com) Aims to resolve patient diagnostic odyssey, often spanning years and multiple misdiagnoses before accurate diagnosisCombines cutting-edge technology and streamlined CE-IVD bioinformatics pipeline with the CENTOGENE Biodatabank, consisting of approximately 700,000 patients representing over 120 highly diverse countriesSignificantly reduces...https//www.marketscreener.com/quote/stock/CENTOGENE-N-V-74010961/news/CENTOGENE-Launches-NEW-CentoGenome-World-s-Most-Comprehensive-Whole-Genome-Sequencing-Solution-for-43474714/?utm_medium=RSS&utm_content=20230412

(marketscreener.com) CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 10, 2022 -- Centogene N.V. , the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its conference schedule for November 2022. The Company’s Pharma and CRO business development team and Diagnostics sales team will be...https//www.marketscreener.com/quote/stock/CENTOGENE-N-V-74010961/news/CENTOGENE-to-Participate-in-Upcoming-Conferences-in-November-42266212/?utm_medium=RSS&utm_content=20221110

The WHO has said calls to treat the coronavirus as endemic are premature as cases in parts of the world remain high.

(marketscreener.com) Meeting expected to occur within 30 days of the FDA's receipt of the meeting requestNEW YORK, Dec. 12, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the company has submitted a Type A Meeting Request to the U.S. Food and...https//www.marketscreener.com/quote/stock/BRAINSTORM-CELL-THERAPEUT-18118014/news/BrainStorm-Cell-Therapeutics-Submits-Type-A-Meeting-Request-to-U-S-Food-and-Drug-Administration-42526499/?utm_medium=RSS&utm_content=20221212

David-Chyddy Eleke in Awka Stakeholders in Anambra State have expressed fear on the likely outbreak of diseases in communities affected by flood, as displaced persons return to their homes. Members

Iron (Fe) accumulates in the brain cortex with aging. A plethora of studies indicate that progressive iron accumulation in the substantia nigra (SN) in the aged human brain is a major risk factor for Parkinson's disease (PD) and other neurodegenerative diseases, but not for everyone. This is because our body has different ways for responding specifically to iron overloading.

TORONTO, Ontario and CAMBRIDGE, Massachusetts, March 13, 2023 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (TSX PMN) (Nasdaq PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced an oral […]

A vaccine that changes the way our body responds to mosquito bites could protect us from diseases the insects carry, and also seems to make mosquitoes lay fewer eggs

Discontinued medicines might be the key to treating many rare diseases.

The big idea We combined a machine learning algorithm with knowledge gleaned from hundreds of biological experiments to develop a technique that allows biomedical researchers to figure ...

  The spread of infections in the relief camps is still a worry for the flood-affected residents of Sindh. Six more individuals, including four children, have reportedly died from various diseases in Sindh’s flood-affected areas, according to official health sources. According to reports, a youngster died in Larkana as a result of viral illnesses. In […]

(marketscreener.com) Nearly half of the world'spopulation, or 3.5 billion people, suffer from oral diseases,the majority of them in low- and middle-income countries, theWorld Health Organization said on Thursday. The most common oral illnesses are tooth decay, severe gumdisease, tooth loss and oral cancers, with untreated tooth decayaffecting nearly...https//www.marketscreener.com/news/latest/Nearly-half-of-world-population-suffers-from-oral-diseases-WHO--42346694/?utm_medium=RSS&utm_content=20221117

(marketscreener.com) CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 01, 2022 -- Centogene N.V. , the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its conference schedule for December 2022. The Company’s Pharma and CRO business development team and Diagnostics sales team will be...https//www.marketscreener.com/quote/stock/CENTOGENE-N-V-74010961/news/CENTOGENE-to-Participate-in-Upcoming-Conferences-in-December-42450709/?utm_medium=RSS&utm_content=20221201

(marketscreener.com) Regulatory Authorization Granted to Proceed with ATH434 Phase 2 Clinical TrialMELBOURNE, Australia and SAN FRANCISCO, Sept. 20, 2022 /PRNewswire/ -- Alterity Therapeutics , a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the approval of its Investigational...https//www.marketscreener.com/quote/stock/ALTERITY-THERAPEUTICS-LIM-57143028/news/Alterity-Therapeutics-Receives-U-S-FDA-Approval-for-Investigational-New-Drug-Application-for-ATH434-41816441/?utm_medium=RSS&utm_content=20220920

(marketscreener.com) ProMIS Neurosciences Overview Targeting Misfolded Proteins in Neurodegenerative Diseases NASDAQ PMN Toronto Stock Exchange PMN.TO January 31, 2023 1 ...https//www.marketscreener.com/quote/stock/PROMIS-NEUROSCIENCES-INC-1408989/news/ProMIS-Neurosciences-Corporate-Overview-42870393/?utm_medium=RSS&utm_content=20230201

Researchers rejuvenate a 53-year-old woman's skin by decades, but clinical applications are a way off.

Commentary We don't know much about zoonotic transmission of COVID-19 between humans and animals, but initial data has value.

Two people with beta thalassaemia and one with sickle cell disease no longer need blood transfusions after their blood stem cells were gene edited and put back in their bodies

Jordan Janz knew his gamble on an experimental gene therapy for his rare disease might be paying off when he returned to work and a friend sniffed him.“He said, ‘you have a normal smell, you smell good,’” Janz recalled.

(marketscreener.com) BERWYN, Pa., April 3, 2023 /PRNewswire/ -- Annovis Bio, Inc.  , a clinical-stage drug platform company addressing neurodegenerative diseases, has announced fourth quarter and full year financial results for the period ended December 31, 2022, and reviewed recent accomplishments. ...https//www.marketscreener.com/quote/stock/ANNOVIS-BIO-INC-102588345/news/ANNOVIS-BIO-ANNOUNCES-FOURTH-QUARTER-AND-FULL-YEAR-2022-FINANCIAL-RESULTS-AND-PROVIDES-CORPORATE-UPD-43414190/?utm_medium=RSS&utm_content=20230403

(marketscreener.com) CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Oct. 06, 2022 -- Centogene N.V. , the commercial-stage essential biodata life science partner for rare and neurodegenerative diseases, today announced its partnering conference schedule for October 2022. Company management and the business development team will be attending events in the U.K....https//www.marketscreener.com/quote/stock/CENTOGENE-N-V-74010961/news/CENTOGENE-to-Participate-in-Upcoming-Partnering-Conferences-in-October-41939432/?utm_medium=RSS&utm_content=20221006

(marketscreener.com) First-ever interventional trial for patients with ALSP, a rare and rapidly progressing neurological disease with significant unmet medical needCAMBRIDGE, Mass., Dec. 14, 2022 -- Vigil Neuroscience, Inc. , a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases,...https//www.marketscreener.com/quote/stock/VIGIL-NEUROSCIENCE-INC-131408792/news/Vigil-Neuroscience-Announces-First-Patient-Dosed-in-the-IGNITE-Phase-2-Clinical-Trial-to-Evaluate-VG-42549363/?utm_medium=RSS&utm_content=20221214

The resurgence of polio and the spread of monkeypox proves again that diseases don’t respect borders. No one is safe until we all are We are talking again about polio – a disease that ran rampant in the 1950s, paralysing thousands of children every year. The successful introduction of polio vaccine in 1956 into the UK, and later more widely, has resulted in the elimination of this once dreaded disease from Europe and indeed most of the world. After the successful global eradication of smallpox in 1980, polio is the next human disease on the list targeted for eradication.But for all the...

(marketscreener.com) BERWYN, Pa., Oct. 6, 2022 /PRNewswire/ -- Annovis Bio, Inc. , a late-stage clinical drug platform company addressing neurodegenerative diseases, announced today that the U.S. Food and Drug Administration has authorized the Phase 2/3 clinical study of buntanetap in moderate Alzheimer's Disease . ...https//www.marketscreener.com/quote/stock/ANNOVIS-BIO-INC-102588345/news/Annovis-Bio-Announces-FDA-Authorization-to-Proceed-with-Phase-2-3-Trial-for-Buntanetap-in-Alzheimer-41941550/?utm_medium=RSS&utm_content=20221006

(marketscreener.com) NEW YORK, Nov. 10, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. , a leading developer of cellular therapies for neurodegenerative diseases, today announced that the company has received a refusal to file letter from the U.S. Food and Drug Administration regarding the company's New Biologics License Application for NurOwn for the...https//www.marketscreener.com/quote/stock/BRAINSTORM-CELL-THERAPEUT-18118014/news/BrainStorm-Cell-Therapeutics-Receives-Refusal-to-File-Letter-from-FDA-for-its-New-Biologics-License-42270947/?utm_medium=RSS&utm_content=20221110

A protein called FNIP1 is the critical link between a cell sensing low energy levels and eliminating and replacing damaged mitochondria. The finding will help scientists understand healthy aging, cancerous tumors, neurodegenerative diseases, and beyond.

Understanding when and why a cell dies is fundamental to the study of human development, disease, and aging. For neurodegenerative diseases such as Lou Gehrig’s disease, Alzheimer’s, ...

A spin-out of Queen's University, Re-Vana is working to improve the treatment of eye diseases by reducing the need for frequent drug administrations.Read more Re-Vana Therapeutics raises $11.9m to boost eye disease treatment

FORMER Georgian President Mikheil Saakashvili has been diagnosed with 36 different diseases by doctors, as reported on Tuesday, November 8. Doctors have diagnosed former Georgian President Mikheil Saakashvili with 36 different diseases, including tuberculosis and dementia, his lawyer said. According to Shalva Khachapuridze, tests by doctors have shown the former president, who was also the […]The post British medical expert visits former Georgian President Mikheil Saakashvili after 36 different diseases diagnosis appeared first on Euro Weekly News.

(marketscreener.com) CAMBRIDGE, Mass., Dec. 1, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. , a company developing treatments for severe neurodegenerative diseases, today announced its financial results for the quarter ended September 30, 2022 and provided a business update."During and immediately following the end of the third quarter, NeuroSense achieved...https//www.marketscreener.com/quote/stock/NEUROSENSE-THERAPEUTICS-L-130483704/news/NeuroSense-Announces-Third-Quarter-2022-Financial-Results-and-Provides-Business-Update-42454085/?utm_medium=RSS&utm_content=20221201

Study examined global exposure to PM2.5, a pollutant linked to many diseases.

(marketscreener.com) Highlighting consistent preclinical and clinical data demonstrating the potential of HGF/MET as a neuroprotective and disease-modifying approach to treat neurodegenerative diseases BOTHELL, Wash., Dec. 01, 2022 -- Athira Pharma, Inc. , a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...https//www.marketscreener.com/quote/stock/ATHIRA-PHARMA-INC-112589423/news/Athira-Pharma-to-Host-Virtual-R-D-Event-on-December-7-2022-from-2-00-ndash-3-30-pm-Eastern-time-42452680/?utm_medium=RSS&utm_content=20221201

Small proteins play a critical role in the regulation of immune response, inflammation and neurodegenerative diseases. In order to better detect and study them, scientists at the Max-Planck-Institute for the Science of Light have combined one of the most effective microscopy methods, called iSCAT, with artificial intelligence.

Commentary We don't know much about zoonotic transmission of COVID-19 between humans and animals, but initial data has value.

Although the two diseases share many symptoms, there are several key differences

Common sense is part of the answer

The telehealth service understood the federal health minister to have promised funding would be renewed from July but has learnt the money will only arrive in January.

(marketscreener.com) First-ever interventional trial for patients with ALSP, a rare and rapidly progressing neurological disease with significant unmet medical needCAMBRIDGE, Mass., Dec. 14, 2022 -- Vigil Neuroscience, Inc. , a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases,...https//www.marketscreener.com/quote/stock/VIGIL-NEUROSCIENCE-INC-131408792/news/Vigil-Neuroscience-Announces-First-Patient-Dosed-in-the-IGNITE-Phase-2-Clinical-Trial-to-Evaluate-VG-42549363/?utm_medium=RSS&utm_content=20221214

Although the two diseases share many symptoms, there are several key differences

Small proteins play a critical role in the regulation of immune response, inflammation and neurodegenerative diseases. In order to better detect and study them, scientists at the Max-Planck-Institute for the Science of Light have combined one of the most effective microscopy methods, called iSCAT, with artificial intelligence.

Researchers have discovered that you can inject CRISPR gene editing directly into the bloodstream, potentially leading to effective treatments for many diseases..